ID   COR-L321
AC   CVCL_2414
SY   CORL321
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_2414
DR   Cell_Model_Passport; SIDM00507
DR   Cosmic-CLP; 1322213
DR   DepMap; ACH-001490
DR   ECACC; 96020756
DR   EGA; EGAS00001000978
DR   GDSC; 1322213
DR   GEO; GSM1669702
DR   PharmacoDB; CORL321_248_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54814287
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Heterozygous (DepMap=ACH-001490).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (DepMap=ACH-001490).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0.7%; East Asian, South=0%; South Asian=0%; European, North=67.03%; European, South=32.26% (PubMed=30894373).
ST   Source(s): Cosmic-CLP=1322213; DepMap=ACH-001490
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12,13
ST   D16S539: 11,12
ST   D18S51: 14,15
ST   D21S11: 30
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 10,11
ST   D8S1179: 10,13
ST   FGA: 22
ST   Penta D: 12
ST   Penta E: 7
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 14,17
DI   NCIt; C4878; Lung carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 24
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//